High-dose desvenlafaxine in outpatients with major depressive disorder

CNS Spectrums

Volumn 17, Issue 3, 2012, Pages 121-130

  Ferguson, James M ^a   Tourian, Karen A ^b   Rosas, Gregory R ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Depression; Desvenlafaxine; Outpatients

Indexed keywords

DESVENLAFAXINE;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BREAST DISEASE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; ELECTROCARDIOGRAPHY; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HAMILTON SCALE; HEMATOLOGY; HUMAN; HYPERHIDROSIS; INSOMNIA; LIPID ANALYSIS; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; VISUAL ANALOG SCALE; VITAL SIGN; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869217487     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852912000508     Document Type: Article

References (37)

1. World Health Organization. Depression. Available at: http://www.who.int/mental_health/management/ depression/definition/en/print.html. Accessed June 11, 2008.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. American Psychiatric Association. Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association. Available at: http://www.psych.org/guidelines/mdd2010. Accessed February 1, 2012.
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095-3105.
5. Sheehan DV. Depression: underdiagnosed, undertreated, underappreciated. Manag Care. 2004; 13(suppl 6): 6-8.
6. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002; 105(3): 164-172.
7. Demyttenaere K, Van GE, Gregoire J, et al. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int Clin Psychopharmacol. 1998; 13(1): 11-17.
8. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001; 62(suppl 22): 30-33.
9. Oganesian A, Shilling AD, Young-Sciame R, et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009; 42(2): 47-63.
10. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebocontrolled trial. Int Clin Psychopharmacol. 2008; 23(5): 243-253.
11. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007; 68(5): 677-688.
12. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008; 24(7): 1877-1890.
13. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007; 22(6): 338-347.
14. Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009; 14(3): 144-154.
15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(suppl 20): 22-33.
16. Hamilton M. Hamilton rating scale for depression (Ham-D). In: Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 526-529.
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382-389.
18. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998; 86(1): 102-106.
19. Sheehan DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 113-115.
20. World Health Organization. Wellbeing measures in primary health care/the depcare project. World Health Organization Regional Office for Europe. Available at: http://www.euro.who.int/__data/assets/pdf_file/ 0016/130750/E60246.pdf. Accessed March 20, 2012.
21. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009; 14(4): 183-195.
22. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc; 2011.
23. Paxil [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006.
24. Prozac [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.
25. Celexa [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2011.
26. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2006.
27. Cymbalta [package insert]. New York, NY: Eli Lilly and Company; 2005.
28. Zoloft [package insert]. New York, NY: Roerig; 2006.
29. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998; 59(10): 502-508.
30. Kocsis JH, Thase ME, Trivedi MH, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007; 68(7): 1014-1023.
31. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004; 14(6): 457-470.
32. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000; 61(suppl 11): 37-41.
33. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003; 289(16): 2120-2127.
34. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004; 42(3): 277-285.
35. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005; 10(9): 732-747.
36. Davey P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods. 2002; 48(1): 3-9.
37. Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011; 31(5): 569-576.